Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. (Nasdaq: CRXT) is a specialty pharmaceutical company focused on men's health that reached the public markets through a business combination with Blue Water Acquisition Corp, a blank-check company sponsored by Blue Water Capital LLC, with the merger closing in 2021. The combined entity operates in the specialty pharmaceuticals sector, centering its commercial efforts on JATENZO, an FDA-approved oral testosterone replacement therapy. The September 2022 Form 8-K filing reflects ongoing post-merger corporate disclosure obligations for the Nasdaq-listed company. For complete filing history, sponsor background, and deal analytics on CRXT and the broader SPAC universe, sign up for full data access at SpacDesk.